These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34952161)

  • 1. Animal models of brain-first and body-first Parkinson's disease.
    Van Den Berge N; Ulusoy A
    Neurobiol Dis; 2022 Feb; 163():105599. PubMed ID: 34952161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study.
    Horsager J; Andersen KB; Knudsen K; Skjærbæk C; Fedorova TD; Okkels N; Schaeffer E; Bonkat SK; Geday J; Otto M; Sommerauer M; Danielsen EH; Bech E; Kraft J; Munk OL; Hansen SD; Pavese N; Göder R; Brooks DJ; Berg D; Borghammer P
    Brain; 2020 Oct; 143(10):3077-3088. PubMed ID: 32830221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of nonhuman primate models to understand processes in Parkinson's disease.
    Blesa J; Trigo-Damas I; Del Rey NL; Obeso JA
    J Neural Transm (Vienna); 2018 Mar; 125(3):325-335. PubMed ID: 28357564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein nonhuman primate models of Parkinson's disease.
    Marmion DJ; Kordower JH
    J Neural Transm (Vienna); 2018 Mar; 125(3):385-400. PubMed ID: 28434076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where and how alpha-synuclein pathology spreads in Parkinson's disease.
    Wakabayashi K
    Neuropathology; 2020 Oct; 40(5):415-425. PubMed ID: 32750743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.
    Mammadova N; Baron T; Verchère J; Greenlee JJ; Greenlee MHW
    Methods Mol Biol; 2021; 2224():75-85. PubMed ID: 33606207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced cerebral blood flow in an
    Biju KC; Shen Q; Hernandez ET; Mader MJ; Clark RA
    J Cereb Blood Flow Metab; 2020 Dec; 40(12):2441-2453. PubMed ID: 31856640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
    He Y; Yu Z; Chen S
    ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
    Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
    Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal α-synuclein deposits in Parkinson's disease patients and animal models.
    Veys L; Vandenabeele M; Ortuño-Lizarán I; Baekelandt V; Cuenca N; Moons L; De Groef L
    Acta Neuropathol; 2019 Mar; 137(3):379-395. PubMed ID: 30721408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
    Nielsen SD; Pearson NM; Seidler K
    Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.
    Johnson ME; Stecher B; Labrie V; Brundin L; Brundin P
    Trends Neurosci; 2019 Jan; 42(1):4-13. PubMed ID: 30342839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.